Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have inflicted on approximately 150 million known cases of coronavirus disease 2019 (Covid-19) till date (1). Vaccines and antibody therapies have given us lot of hope to control this pandemic thus controlling the death. The current vaccine strategies are directed at the viral “spike protein or S gene”, but newer viral variants, particularly the S gene variants, weakens this strategy. Thus vaccine resistance (Vaccine Breakthrough Infections both asymptomatic and illness) has emerged a new challenge for our scientists and physicians. Recently, New York City has seen a troubling increase in viral variants like B.1.1.7 (first identified in the United Kingdom in 26.2% of the cases) that accounted for more than 72% of new cases as of March 2021 and B.1.526 variant first identified in New York City (in 42.9%) (2). These challenges force us to continually increase testing and sequencing of the SARS-CoV-2 virus. This will help to understand the transmissibility, virulence, and ability of variants to evade current vaccines. Currently, authorized and recommended vaccines are mainly of three types.
- mRNA Vaccine. RNA sequence representingSARS-CoV-2 is inje
MolQ Diagnostic Lab offers single gene and panel of genes analysis for the various cancer syndromes. Mutations are screened by targeted sequencing using NGS. The panel targets 54 disease syndromes.
Our home sample collection team will arrange pickup of your specimens on request. Pickup times are accommodated to patient’s need. We deliver pathology test report’s to clients via e-mail, mail & SMS.
MolQ is NABL Certified Pathology and Diagnostic Lab based in Gurgaon, we have multiple franchises across PAN India serving thousands of patients everyday. We welcome new partners to join us.
MolQ Diagnostic Lab provides a complete interpretation of genetic and pathology test results; all molecular tests are reviewed by experts who provides detailed summary of the findings.